Lupus
With numerous national and international meetings taking place throughout the year, choosing which conferences to attend can be difficult. While scientific programs remain a major draw, opportunities for networking, collaboration, career development and presenting research are often just as valuable. To help identify the meetings making the biggest impact across rheumatology, we asked members of the touchIMMUNOLOGY community to share the conferences they're prioritizing this year and what makes them worth attending.
Dapirolizumab pegol has shown promising results for the treatment of systemic lupus erythematosus in the phase 3 PHOENYCS GO trial. We spoke with Dr Janet Pope about a secondary analysis of the study, presented at EULAR 2026, investigating the treatment's effects on anti-dsDNA antibodies and complement proteins, and what these findings reveal about disease activity and potential clinical benefit.
Could personalized non-pharmacological care improve outcomes for people living with systemic lupus erythematosus and systemic sclerosis? In this interview from EULAR 2026, Dr Ioannis Parodis discusses the evidence underpinning EULAR recommendations and explores how patient education, psychosocial support and tailored lifestyle interventions can complement pharmacological treatment.
Meet the immunologists redefining the future of practice, research, and technology! The touchIMMUNOLOGY Future Leaders 2026 have been nominated by the immunology community to recognize the rising stars shaping the future of research and clinical care. These clinicians, researchers and innovators are driving progress across the specialty — from advancing clinical practice to challenging convention and improving patient outcomes.
Dr Nancy Lane (UC Davis, Sacramento, CA, USA) highlights the latest in lupus care, GLP-1 therapies for pain and comorbidities, and new tools for osteoporosis risk assessment—showing how cutting-edge research is giving rheumatologists more ways than ever to improve patient outcomes.
July delivered a broad range of important updates in immunology, spanning regulatory approvals, new therapeutic formulations, and key clinical trial results across autoimmune, inflammatory, and rare diseases. This monthly roundup highlights the most significant developments, including first-in-class oral therapies, expanded paediatric indications, and both positive and negative late-phase trial outcomes.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this edition of our Future Leaders series, we speak with Dr. Santhanam Sham, a rising star in rheumatology. As a Senior Consultant at Kauvery Hospitals, Chennai, Dr. Sham is dedicated to advancing research on autoimmune diseases like SLE and vasculitis, while also fostering patient-centric care and embracing cutting-edge medical technologies.
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disorder affecting skin, joints, kidneys, the heart, lungs, the brain and blood cells, and is characterized by heterogeneous presentations and severity. It is more common in females than males, with a ratio ...
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with ...
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of ...
Systemic lupus erythematosus (SLE) is a chronic, relapsing and remitting autoimmune disease,1 affecting 13–7,714 per 100,000 individuals.2 Inflammation in SLE can lead to tissue damage in any organ system, frequently due to acute flares,1 with commonly affected organ systems including the cardiopulmonary, ...
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis ...
Women with rheumatic disease, such as systemic lupus erythematosus, are often prescribed azathioprine to control disease activity during pregnancy. However, the changes in azathioprine metabolite levels throughout pregnancy in such women are yet to be well-characterized. It was a pleasure ...
In women with systemic lupus erythematosus (SLE), ill-timed pregnancies can cause complications related to teratogen use and SLE activity. In this touchIMMUNOLOGY interview we spoke with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study implementing the HOP-STEP ...
WILLOW is a phase II, double-blind study investigating enpatoran for the treatment of systemic and/or cutaneous lupus erythematosus (NCT05162586). touchIMMUNOLOGY were delighted to speak with Dr. David R Pearson (University of Minnesota, Minneapolis, MN, USA) about the findings from preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran, and about the aims, eligibility criteria and primary and secondary outcome measures of the WILLOW study. The abstract 'Enpatoran: Preclinical Evidence Supporting Glucocorticoid Dose Reduction and Phase II Study Design in Patients with SLE and/or CLE (WILLOW).' (Abstract number: 1230) was presented at EADV 2022, 7-10 September, 2022. Questions Could you tell us a little about the preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran? (0:20) What were the findings of these studies? (1:23) What are the aims, design and eligibility criteria of the WILLOW study? (3:13) What are the primary and secondary outcome measures of the study? (3:44) Disclosures: David R Pearson discloses consulting for Biogen, Inc and receiving grant/ research support from Corbus, EMD Serono, Emerald Health, Kadmon, Pfizer, and Priovant. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.Â
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
